ArticlePlant biotechnology journal2026
Auxin-Induced Nicotine Inhibition Is Mediated by NaARF5 Through the Suppression of NaERF1-Like Expression and Interaction With NaERF1-Like in Nicotiana attenuata.
Article in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nicotine is the most abundant alkaloid produced by Nicotiana species against insect herbivores. Although it has been known for decades that auxin can strongly inhibit nicotine biosynthesis, the underlying mechanisms have remained unclear. Here we demonstrated that NaERF1-like, the orthologue of NtERF199, is a key regulator of nicotine biosynthesis through gene-editing and stable overexpression. NaERF1-like expression was strongly inhibited by auxin treatments, suggesting that it is a target gene regulated by auxin. Yeast two-hybrid screening revealed that NaARF5, an auxin response factor, interacts with NaERF1-like. This interaction was further confirmed by GST pull-down, bimolecular fluorescence complementation, and split-luciferase complementation. NaARF5 acts as a key negative regulator of nicotine production since both the expression of nicotine-related genes and nicotine production increased significantly in NaARF5 mutants generated by CRISPR/Cas9 but was severely impaired in NaARF5 overexpression lines. Notably, the inhibition of nicotine-related genes by auxin, including NaERF1-like, is alleviated in NaARF5 mutants. Furthermore, the interaction of NaARF5 with NaERF1-like reduced the binding and activating ability of NaERF1-like to the promoter of NaPMT1.1, a key enzyme gene involved in nicotine biosynthesis, as well as the transcriptional activity of NaQPT2. Thus, we uncovered a new auxin-mediated regulatory pathway for the inhibition of nicotine biosynthesis through NaARF5 by targeting NaERF1-like. Our findings provide novel insights into the molecular mechanisms underlying the inhibition of defensive metabolites by auxin and establish NaARF5 as a valuable breeding target for manipulating nicotine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.